During April, the top-rated multi-state podiatry practices emphasizes daily hygiene, exercise, preventive care and early intervention to resolve minor foot issues before they can become major health problems.
Read More"This isn't just about paperwork - it's about a pattern of disregard for the law," said Duane Boise CEO MMJ International Holdings. "The DEA can't demand compliance from others while ignoring its own obligations."
Aarathi D. Haig, a DEA attorney central to the agency's controversial handling of MMJ Biopharma Cultivation's Bulk Manufacturers cannabis research application, is not in good standing with the New Jersey Bar. A February 2023 letter from the New Jersey Board of Bar Examiners states Haig is ineligible for a Certificate of Good Standing
Read MoreSea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system)
Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS)
Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA
Inotiv Inc will assist Sea to quantify SPM-0404 levels in Clinical Phase 1 and Ph.1b Trials
Exclusive documents obtained reveal DEA Attorney Aarathi Haig, the key DEA attorney in MMJ's cannabis research constitutional Administrative Law Judge case, is ineligible for a Certificate of Good Standing in the N.J. Bar due to compliance failures.
Read More
House resolution, national campaign, and patient voices shine a spotlight on one of the most prevalent-but misunderstood-autoimmune diseases.
Read More
Innovative dual teleconsultation platform enabling a remote physician to establish a simultaneous video call with the patient while also connecting in real-time with a healthcare assistant/nurse equipped with augmented reality (AR) smart glasses for more precise patient clinical assessments.
Read More
The global functional mushroom market is projected to reach $19.3 billion by 2030, driven by cutting-edge research revealing their potential to enhance memory, nerve growth, and overall cognitive health.
Read More
This April Fools' Day, the DEA Diversion isn't just the punchline-it's the entire joke.
For the DEA, the joke's on them-and MMJ's legal team is doubling down. As Duane Boise MMJ's CEO quipped: “We'd send them a ‘Sorry For Your Loss' card, but we're too busy preparing for FDA clinical trials.”
Read More
During the PFATS meeting at the NFL Medical Summit, the inventors of sustained acoustic medicine will demonstrate the technology and present research showing its effectiveness in accelerating soft tissue healing.
Read More-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
Read More
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023
The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million
Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025
FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer
REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast
Read MoreCompany Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024
Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26
Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially
Stockholders' Equity Was $7.1 Million at Year End
Pending Acquisitions Remain on Track; TRNR Expects More than $50M in 2025 Pro Forma Revenue
Read More
"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation."
DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer.
Read More
